Haematologic adverse effects of treatment of chronic viral hepatitis B and C;Hematologické nežiaduce účinky liečby chronickej vírusovej hepatitídy B a C

Klinicka Mikrobiologie a Infekcni Lekarstvi

Volumn 14, Issue 2, 2008, Pages 74-78

  Porubčin, Štefan ^a   Schreter I ^a   Kristian, P ^a   Pellova A ^a  

^a FN L Pasteura ^*  (Slovenia)

Author keywords

Adverse effects; Chronic hepatitis B; Chronic hepatitis C; Interferon; Pegylated interferon; Ribavirin

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ANTIVIRUS AGENT; HEMOGLOBIN; PEGINTERFERON ALFA-2B;

ANEMIA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HEMATOLOGIC DISEASE; HEMOGLOBIN DETERMINATION; HEPATITIS B; HEPATITIS C; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; SEX DIFFERENCE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION;

ANEMIA; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBINS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; NEUTROPENIA; RIBAVIRIN; THROMBOCYTOPENIA;

EID: 47849090917     PISSN: 1211264X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Mc Intyre N, Benhamon J.P. Oxford Textbook of Clinical Hepatology. Volume 1. Oxford, New York, Tokyo, Oxford Medical Publication; 1991.
2. Jacobson IM. Therapeuic options for chronic hepatitis B: considerations and controversies. Am J Gastroenterol. 2006;101:13-18.
3. Min AD, Dienstag JL. Oral antivirals for chronic hepatitis B. Clin Liver Dis. 2007 Nov;11(4):851-68.
4. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36:21-29.
5. Nakamuta M, Ohashi M, Fukutomi T. Rise of plasma myeloperoxidase during interferon therapy. J Gastroenterol Hepatol. 1995;10:277-280.
6. Van Vlierberghe H, Delanghe JR, De Vos M, et al. Factors influencing ribavirin induced hemolysis. J Hepatol. 2001;34:911-916.
7. Hoffmann-La Roche. PEGASYS (Peginterferon Alfa-2A). Complete product information. Nutley, NJ 07110-1199: December 2003.
8. Schering Plough. PEG-intron (peginterferon alf-2b) Package Insert. Kenilworth, NJ: 2001.
9. De Franceschi L, Fattovich G, Turtim F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 2000;31:997-1004.
10. Sulkowski M, Wasserman R, Ball L, et al. Changes in hemoglobin during therapy with interferon alpha-2b plus ribavirin in IFN aipha-naive and fFN alpha-experienced patients (Abstract 834). Program and abstracts of the 51th Annual Meeting of the American Association for the Study of Liver diseases; 2000 October 27-31, Dallas, USA.
11. CDC. Recommendations for the prevention and control of hepatitis C virus infection and HCV-related chronic disease. MMWR. 1998;47:1-39.
12. Takaki S, Tsubota A, Hosaka T, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa-2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol. 2004;39:668-673.
13. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26:112-121.
14. Manns MP, Mc Hutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965.
15. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.